Appeals Court Affirms Pfizer Marketing Exclusivity For Diflucan

Law360, New York (April 28, 2004, 12:00 AM EDT) -- The U.S. Court of Appeals for the District of Columbia has upheld a lower court’s decision that extends Pfizer’s U.S. marketing exclusivity for blockbuster antifungal drug Diflucan until late July.

The decision acknowledged that Pfizer, because it had completed pediatric trials of the medicine, was entitled to keep its U.S. market exclusivity on the drug six months beyond the expiration of its U.S. patent.

The six-month extension had been challenged by Indian generic drug maker Ranbaxy Laboratories Ltd. Ranbaxy had claimed that generic version of Diflucan...
To view the full article, register now.